We are a biotech firm that has identified a drug for treatment of acute critical illness and an accompanying biomarker ie, precision medicine. We have PoC from several phase 1A/1B/2A trials that the drug is safe and reduces organ failure. The drug as such is known for other indications ie, our treatment is a second medical use. We have patents covering treatment, biomarker and use of the drug. The next step is to conduct a larger phase 2B trial.